These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 29507068)
1. Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model. Wu J; Racine F; Wismer MK; Young K; Carr DM; Xiao JC; Katwaru R; Si Q; Harradine P; Motyl M; Bhagunde PR; Rizk ML Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507068 [TBL] [Abstract][Full Text] [Related]
2. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]
3. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Smith JR; Rybak JM; Claeys KC Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929 [TBL] [Abstract][Full Text] [Related]
4. A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam. Bhagunde P; Zhang Z; Racine F; Carr D; Wu J; Young K; Rizk ML Int J Infect Dis; 2019 Dec; 89():55-61. PubMed ID: 31479762 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. Karlowsky JA; Lob SH; Kazmierczak KM; Hawser SP; Magnet S; Young K; Motyl MR; Sahm DF J Antimicrob Chemother; 2018 Jul; 73(7):1872-1879. PubMed ID: 29659861 [TBL] [Abstract][Full Text] [Related]
7. Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections. Kaye KS; Boucher HW; Brown ML; Aggrey A; Khan I; Joeng HK; Tipping RW; Du J; Young K; Butterton JR; Paschke A Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094127 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Hirsch EB; Ledesma KR; Chang KT; Schwartz MS; Motyl MR; Tam VH Antimicrob Agents Chemother; 2012 Jul; 56(7):3753-7. PubMed ID: 22526311 [TBL] [Abstract][Full Text] [Related]
10. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202 [TBL] [Abstract][Full Text] [Related]
11. Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors. Bhagunde P; Chang KT; Hirsch EB; Ledesma KR; Nikolaou M; Tam VH Antimicrob Agents Chemother; 2012 May; 56(5):2237-40. PubMed ID: 22330927 [TBL] [Abstract][Full Text] [Related]
12. Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City. Lapuebla A; Abdallah M; Olafisoye O; Cortes C; Urban C; Landman D; Quale J Antimicrob Agents Chemother; 2015 Aug; 59(8):5029-31. PubMed ID: 26014931 [TBL] [Abstract][Full Text] [Related]
13. Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017. Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF Diagn Microbiol Infect Dis; 2019 Oct; 95(2):212-215. PubMed ID: 31174995 [TBL] [Abstract][Full Text] [Related]
15. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination. Mansour H; Ouweini AEL; Chahine EB; Karaoui LR Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649 [TBL] [Abstract][Full Text] [Related]
16. Effect of Porins and bla Balabanian G; Rose M; Manning N; Landman D; Quale J Microb Drug Resist; 2018 Sep; 24(7):877-881. PubMed ID: 29782237 [TBL] [Abstract][Full Text] [Related]
17. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection. Lucasti C; Vasile L; Sandesc D; Venskutonis D; McLeroth P; Lala M; Rizk ML; Brown ML; Losada MC; Pedley A; Kartsonis NA; Paschke A Antimicrob Agents Chemother; 2016 Oct; 60(10):6234-43. PubMed ID: 27503659 [TBL] [Abstract][Full Text] [Related]